Scholar IQ
Help
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewKey papers
ScholarIQanswers from OpenAlex

The Lancet Oncology

JournalCitation impact & published research
12,143
Works
1,055,874
Citations
520
h-index
6,300
APC (USD)
What are the most-cited papers on The Lancet Oncology?
ScholarIQmost cited works
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman, Ray McDermott, Joseph L. Leach, Sara Lonardi, Heinz‐Josef Lenz, Michael A. Morse, Jayesh Desai, Andrew Hill, Michael D. Axelson, Rebecca A. Moss, Monica V. Goldberg, Z. Alexander Cao, Jean-Marie Ledeine, Gregory A. Maglinte, Scott Kopetz, Thierry André
The Lancet Oncology. 20172,843 CitationsOPEN ACCESS
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
The Lancet Oncology. 20152,672 Citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Andrea L. Webber, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo, Angela Alistar, Jamil Asselah, Jean‐Frédéric Blanc, Ivan Borbath, Timothy Lewis Cannon, Ki Y. Chung, Allen Lee Cohn, David Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita
The Lancet Oncology. 20182,543 Citations
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha H. Shah, Ronnie Shapira‐Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L. Kindler, José A. López-Martín, Wilson H. Miller, Antoîne Italiano, Steven Kao, Sarina A. Piha‐Paul, Jean‐Pierre Delord, Robert R. McWilliams, David Fabrizio, Deepti Aurora-Garg, Lei Xu, Fan Jin, Kevin Norwood, Yung‐Jue Bang
The Lancet Oncology. 20202,526 CitationsOPEN ACCESS
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour, Jan Bogaerts, Andrea Perrone, Robert Ford, Lawrence H. Schwartz, Sumithra J. Mandrekar, Nancy U. Lin, Saskia Litière, Janet Dancey, Alice Chen, F. Stephen Hodi, Patrick Therasse, Otto S. Hoekstra, Lalitha Shankar, Jedd D. Wolchok, Marcus Ballinger, Caroline Caramella, Elisabeth G.E. de Vries
The Lancet Oncology. 20172,432 CitationsOPEN ACCESS
Related on ScholarIQ
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Paper
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Paper
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Paper
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Paper
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Paper
Cancer-related inflammation and treatment effectiveness
Paper
470M+ articles · free account